Show simple item record

dc.contributor.authorKelley, R. K.
dc.contributor.authorVogel, A.
dc.contributor.authorFuruse, J.
dc.contributor.authorEdeline, J.
dc.contributor.authorFinn, R.
dc.contributor.authorRen, Z. G.
dc.contributor.authorSu, S. C.
dc.contributor.authorMalhotra, U.
dc.contributor.authorSiegel, A. B.
dc.contributor.authorValle, Juan W
dc.date.accessioned2020-12-08T05:36:26Z
dc.date.available2020-12-08T05:36:26Z
dc.date.issued2020en
dc.identifier.citationKelley RK, Vogel A, Furuse J, Edeline J, Finn R, Ren ZG, et al. Keynote-966 trial in progress: pembrolizumab added to gemcitabine and cisplatin for advanced biliary tract cancer. Hepatology. 2020;72:697A-A.en
dc.identifier.urihttp://hdl.handle.net/10541/623460
dc.description.abstractBackground: Biliary tract cancer (BTC), comprising intra- and extra-hepatic cholangiocarcinoma and gallbladder cancer, is a rare and aggressive malignancy. Most patients (pts) present with advanced or unresectable disease, for which the current standard of care is gemcitabine plus cisplatin. Median survival for these pts is only 12 inhibitor that has demonstrated modest antitumor activity as monotherapy in pts with previously treated BTC and has improved survival when used in combination with platinum-based chemotherapy in other cancer types. months, highlighting the need for more effective therapies. Pembrolizumab is a PD-1 inhibitor that has demonstrated modest antitumor activity as monotherapy in pts with previously treated BTC and has improved survival when used in combination with platinum-based chemotherapy in other cancer types.en
dc.language.isoenen
dc.titleKeynote-966 trial in progress: pembrolizumab added to gemcitabine and cisplatin for advanced biliary tract canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDivision of Hematology/Oncology, UCSF, San Francisco, CA, USAen
dc.identifier.journalHepatologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record